

# Neurochemical Research

## The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats --Manuscript Draft--

<b>Manuscript Number:</b>	NERE2930R2
<b>Full Title:</b>	The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats
<b>Article Type:</b>	Original
<b>Keywords:</b>	Nogo-66 receptor; Axon; Cortical infarction; regeneration; Signal pathway
<b>Corresponding Author:</b>	Xin Li CHINA
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Hong Zhan
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Hong Zhan Shu-Jie Sun Jie Cai Ying-Qing Li Chun-Lin Hu Daniel H.S. Lee Kwok-Fai So Xin Li
<b>Order of Authors Secondary Information:</b>	

**The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats**

Running title: The neuroprotection of NgR1 antagonist on cortical axons

Hong Zhan<sup>1,6</sup>, Shu-Jie Sun<sup>4,6</sup>, Jie Cai<sup>1</sup>, Ying-Qing Li<sup>1</sup>, Chun-Lin Hu<sup>1</sup>, Daniel H.S. Lee<sup>3</sup>, Kwok-Fai So<sup>2,5</sup>, Xin Li<sup>1</sup>

<sup>1</sup>Department of Emergency, The First Affiliated Hospital, Sun Yat-sen University, 58 ZhongShan II, Guangzhou, Guangdong, 510080, China

<sup>2</sup>Department of Anatomy and The State Key Laboratory of Brain and Cognitive sciences, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China

<sup>3</sup>Roche R&D Center (China) Ltd. 720 Cai Lun Road, Building, Pudong, Shanghai 201203, China

<sup>4</sup>Emergency Department, East Hospital of TongJi University, 150 Jimo Road, Shanghai, People's Republic of China

<sup>5</sup>GHM Institute of CNS Regeneration, Jinan University, Guangzhou, China

<sup>6</sup>These authors contributed equally to this work.

**Correspondence to:**

**Xin Li, MD**

Associate Professor

Department of Emergency

The First Affiliated Hospital

Sun Yat-sen University

58 ZhongShan Road II, Guangzhou, Guangdong, 510080, China

Telephone: +86-20-28823350

Fax: +86-20-28823350.

E-mail: xlidoct@qq.com

## Abstract

1 We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of  
2 cortical axons after cortical infarction in rats. The cortical infarction was induced by  
3  
4 photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was  
5  
6 injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of cortical axons after cortical infarction in rats. The cortical infarction was induced by photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using histochemical and transmission-electron microscope techniques. The involved signaling pathways, which include RhoA, JNK, c-JUN and ATF-2, were detected by Western blot. Serious pathologies were found in the brains of the rats after injury, including edemas in the axoplasms of axons that have no medulla sheath and a thickening or shrinkage in the sheath of the axons that have medulla sheathes. However, these pathologies improved after sNgR-Fc treatment. The levels of GTP-RhoA, p-JNK, p-c-JUN and p-ATF-2 in the PCI group were increased when compared with their levels in the sham-operation group ( $P < 0.05$ ), and animals receiving the sNgR-Fc treatment showed lower expression levels of these proteins when compared with the sham-operation group ( $P < 0.05$ ). Our results suggest that sNgR-Fc can alleviate the pathological changes of axons following cortical infarction via decreasing the activation of RhoA/JNK signaling pathways.

**Key words:** Nogo-66 receptor; Axon; Cortical infarction; Regeneration; Signal pathway

## Introduction

1 A brain infarction (also known as an ischemic stroke) is caused by the blockage of a cerebral  
2 artery by a blood clot, which results in the following effects: a critical reduction in blood flow,  
3  
4 ischemia, anoxia, and, finally, ischemic necrosis or encephalomalacia in the brain. This  
5  
6 condition is characterized clinically by high morbidity, high mortality, high disability rate,  
7  
8 high recurrence rates, and it is difficult to treat. Because our population is aging, stroke is  
9  
10 becoming a more serious threat and an urgent medical problem. Previous studies have shown  
11  
12 that the central nerve system cannot regenerate after injury, as a result of factors that include  
13  
14 the insufficiency of neural progenitor cells (NPCs) and a microenvironment that inhibits the  
15  
16 regeneration of neurons [1]. Recent studies have demonstrated that the inhibition of axon  
17  
18 regeneration after injuries to the central nervous system (CNS) were associated with several  
19  
20 CNS myelin proteins, including Nogo-A, myelin-associated glycoprotein (MAG), and  
21  
22 oligodendrocyte myelin glycoprotein (OMgp). These three proteins bind to the Nogo-66  
23  
24 receptor (NgR1), which then leads to the downstream activation of RhoA (Ras homolog gene  
25  
26 family, member A) via two transmembrane proteins, LINGO-1 and p75; these proteins inhibit  
27  
28 the activity in neurons and their axons [2–4]. Jun N-terminal kinases (JNKs) are intracellular  
29  
30 molecules related to stress stimuli. The activation of these molecules mediates many types of  
31  
32 injury-induced apoptosis and plays a role in the regeneration of axons. However, the role of  
33  
34 the JNK-signaling pathway in the presence of a brain infarction is still unclear. The  
35  
36 administration of sNgR-Fc, a recombinant rat soluble NgR-Fc fusion protein [5], has been  
37  
38 found to block the interaction of myelin proteins with NgR1 effectively and to promote the  
39  
40 regeneration of axons in rodent models of CNS injuries such as spinal cord injury [6–10]. A  
41  
42 previous study has shown that anti-Nogo-A antibody promoted the behavioral outcome and  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 corticospinal plasticity in a rat stroke model [11]. In this study, we established a stroke model  
2 in rats and observed the effects of sNgR-Fc on the axonal pathology and the involved  
3  
4 RhoA/JNK signaling pathways after cortical infarction.  
5  
6  
7  
8  
9

## 10 **Experimental Procedure**

### 11 **Animals**

12  
13 The animal experiments were approved by the Committee for the Use of Live Animals in  
14  
15 Teaching and Research at the Sun Yat-sen University. All of the experiments were performed  
16  
17  
18 in a fully randomized and blinded fashion.  
19  
20  
21  
22

### 23 **Photothrombotic cortical injury**

24  
25 Photothrombotic ischemia was induced in the rat parietal cortex using previously described  
26  
27 methods [9,11,12] with the modifications as outlined below. Twenty seven male SD rats  
28  
29 weighing 250 g were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and  
30  
31 xylazine (8 mg/kg). Dilute Rose-Bengal in saline (40 mg/kg body weight) was infused into  
32  
33 the femoral vein. The portion of the skull exposed at 3 mm posteriorly to the bregma and 3  
34  
35 mm laterally from the midline was illuminated with a cold, white light beam (Volpi Intralux  
36  
37 6000, 150 W; Volpi AG, Schlieven, Switzerland) for 8 min at maximum output via a  
38  
39 fiber-optic bundle with a 10 mm aperture. The animals were randomly grouped into  
40  
41 sham-operation (operation + Rose-Bengal), PBS (operation + Rose-Bengal + PBS), or  
42  
43 sNgR-Fc (operation + Rose-Bengal + sNgR-Fc) groups ( $n = 9$  for each group). A solution of  
44  
45 sNgR-Fc (400  $\mu$ g/kg body weight) in 10 $\mu$ l PBS or equivalent PBS was only once injected  
46  
47 into the ipsilateral ventricle using a 26-gauge sterile microsyringe 24 h after photothrombotic  
48  
49 cortical injury [11]. The site of injection was at 1 mm posteriorly to the bregma and 1.5 mm  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 laterally from the midline, and the depth of injection was about 3.5~4.0 mm. For each group,  
2 the whole cerebrum of 3 animals was collected 24 h after injury for tissue staining. The  
3  
4 ipsilateral cortex of peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm  
5  
6  
7 laterally from the midline of rats was collected at 27 d after injury for electron microscopy  
8  
9  
10 examination ( $n = 3$  for each group) and for Western blotting ( $n = 3$  for each group).  
11  
12  
13  
14

### 15 **Triphenyltetrazolium chloride staining**

16  
17  
18 To evaluate the extent of cortical infarction, we used 2, 3, 5-Triphenyltetrazolium chloride  
19  
20  
21 (TTC) to assess cerebral injury. At 24 h after PCI, the animals were sacrificed using an  
22  
23  
24 overdose of pentobarbital sodium (150 mg/kg, Alcon-Couvreur, Rijksweg, Puurs, Belgium).  
25  
26  
27 The brains were removed immediately and then were chilled at  $-30\text{ }^{\circ}\text{C}$  for 4 min to slightly  
28  
29  
30 freeze the tissue. Two-mm coronal sections from the olfactory bulb to the cerebellum were  
31  
32  
33 prepared, stained with 1.5% TTC (Genetime) at  $37\text{ }^{\circ}\text{C}$  for 30 min, and fixed in 10% buffered  
34  
35  
36 formalin solution.  
37

### 38 **Transmission electron microscopy**

39  
40  
41 Seven days after PCI, the peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm  
42  
43  
44 laterally from the midline on the injury side was removed and immediately cut into  $0.5\text{ cm}^3$   
45  
46  
47 cubes at  $0\text{ }^{\circ}\text{C}$ , fixed with 4% paraformaldehyde for 4 h, and washed with PBS. Then, the  
48  
49  
50 tissue was fixed with 2% osmic acid for 2 h, washed with pure water, dehydrated with a  
51  
52  
53 mixture of ethanol, propylene oxide, and resin, embedded in pure resin, and ultramicrocut  
54  
55  
56 and stained with uranyl acetate and lead citrate [13, 14]. The sections were observed under an  
57  
58  
59 HE-800 transmission electron microscope (Hitachi, Japan).  
60

### 61 **Western blotting**

1  
2 The cortex from the injury side was collected at 7 days after injury and homogenized in a  
3  
4 lysis buffer (in mM: Tris, 10, pH 7.4; NaCl, 150; EDTA, 1; EGTA, 1; 10% protease inhibitor,  
5  
6 1% phosphatase inhibitor), and incubated on ice for 30 min. The protein lysate was then  
7  
8 centrifuged at 13,500 rpm for 30 min at 4 °C. The supernatant was aliquoted and stored at  
9  
10 -80 °C until its use. The supernatant was measured for its protein concentration using a  
11  
12 Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 40 µg aliquot of protein  
13  
14 from each sample was subjected to 5–12% SDS–polyacrylamide gel electrophoresis and  
15  
16 transferred onto a PVDF membrane. Each membrane was blocked with 5% non-fat milk and  
17  
18 2% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h  
19  
20 at room temperature and then probed with rabbit anti-p-JNK (Cell Signaling Technology,  
21  
22 MA, USA), anti-p-c-JUN (Cell Signaling Technology), p-ATF-2 (Cell Signaling  
23  
24 Technology), total-JNK (Cell Signaling Technology) and total-RhoA antibodies at 4 °C  
25  
26 overnight. As a gel loading control, β-actin was used. After washing, the membranes were  
27  
28 incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:2000;  
29  
30 DakoCytomation, Denmark). Its immunoreactivity was visualized using the Amersham  
31  
32 enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA). The protein loading  
33  
34 was controlled using the goat antibody against β-actin (C-11; Santa Cruz Biotechnology).  
35  
36 The quantification of the results was performed by densitometry, and the results were  
37  
38 analyzed as total integrated densitometric values (arbitrary units). The protein GTP-RhoA  
39  
40 was pulled down using a RhoA activation assay kit, according to the manufacturer's  
41  
42 instruction (Cytoskeleton, Denver, CO, USA) and assayed by Western blotting using an  
43  
44 antibody against RhoA (Cytoskeleton). All experiments for Western blotting were performed  
45  
46 with 3 animals in each group, and the samples were run on the gels as individual animals.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Data and statistical analysis

1           The values are presented as the mean  $\pm$  SD. The statistical analyses was performed  
2  
3  
4 using Student's t-test for comparisons between two groups or the one-way analysis of  
5  
6 variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) for comparisons of  
7  
8 more than two groups. The data were analyzed statistically with the software SPSS 12.0. The  
9  
10 significance level was set at  $P < 0.05$ .  
11  
12  
13  
14  
15  
16  
17

## Results

### Measurement of brain infarct volume and identification of blood brain barrier integrity

21           After TTC staining, the rats in the sham group did not appear to have any infarctions (Fig.  
22  
23 1b). However, the right parietal lobes of the rats 24 h after PCI presented pale infarctions that  
24  
25 were bowl-shaped, with the bottom pointing to the lateral ventricle; these infarctions affected  
26  
27 the entire cortex. The total infarct volumes were  $297.1 \pm 23.4 \mu\text{l}$  in the PBS group and  
28  
29  $285.4 \pm 19.7 \mu\text{l}$  for the sNgR-Fc group respectively before the treatment. The locations of  
30  
31 the infarctions were stable, and the infarctions showed similar volumes to those in the rats  
32  
33 (Fig. 1).  
34  
35  
36  
37  
38  
39  
40  
41  
42

### Pathological changes of axons

43           The morphology of ischemic penumbra on the injury side was evaluated using TEM at 7 days  
44  
45 after PCI. Compared with the normal axons observed in the sham group (Fig. 2a), more  
46  
47 serious pathologies were observed in the PCI group (Fig. 2b). For the axons without a  
48  
49 medulla sheath, many edemas, dilutions of cytoplasmic matrices, and axonal fusions or  
50  
51 dissolutions were found. Occasionally, we observed that oligodendrocytes appeared to  
52  
53 “swallow” the axons (Fig. 2b). For axons with a medulla sheath, compared with the sham  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

group, thickening or shrinking was more in the axoplasm of the fibers, and amyloidosis and swollen axons were observed at a higher rate. In addition, the axolemma were found to be separated from the inner layers of the myelin (Fig. 2e). In addition, there were only minor pathological changes, including slight nuclear edemas with complete nucleoli, slightly swollen mitochondria, and slightly widened endoplasmic reticula with complete ribosomes and Golgi bodies. In unmyelinated axons, there were some axonal edemas, axonal deformities, and dilutions of cytoplasmic matrices; in addition, there were no axonal fusions or cytophagic effects of oligodendrocytes (Fig. 2c). In myelinated axons, the morphology of axons was almost normal. There was little demyelination and no amyloidosis of the myelin sheath was found (Fig. 2f). Compared with normal synapses (Fig. 2g), the synaptic cleft widened, and there was edema in the PBS group (Fig. 2h). However, no clear edema or widening of the synaptic cleft was observed in the group that received the sNgR-Fc treatment (Fig. 2i).

#### **sNgR-Fc inhibited RhoA signal pathway**

The level of GTP-RhoA in the PBS group was significantly higher than that in the sham-operation group ( $P < 0.05$ ). After treatment with sNgR-Fc, the level of GTP-RhoA was significantly decreased. Moreover, the level of Total-RhoA was not different among the three groups (Fig.3, Table 1). These data indicate that sNgR-Fc could decrease the activation of RhoA.

#### **sNgR-Fc inhibit the activation of SAPK/JNK signal pathway**

The levels of p-JNK1, 2 and its downstream targets, p-c-JUN and p-ATF-2, in the cortex around the infarcts in the PCI group were significantly higher compared with those in the sham operation group ( $P < 0.05$ ). In contrast, the cortex in the sNgR-Fc-treated group showed,

1  
2 on average, reductions in the levels of p-JNK1, 2, p-c-JUN and p-ATF-2 to their basal levels  
3  
4 ( $P < 0.05$ ). The levels of total JNK1, 2 were not different among the three groups ( $P > 0.05$ ).  
5  
6 These results demonstrate that the cortical infarction injury activates the SAPK/JNK signal  
7  
8 pathway and that treatment with sNgR-Fc has the potential to decrease or prevent this  
9  
10 activation (Fig.3, Table 1).  
11  
12  
13  
14

## 15 **Discussion**

16  
17  
18 Watson et al reported a stroke model induced by a photochemical method in 1985 [12]. The  
19  
20 principle underlying this model was based on a photochemical reaction. Following the  
21  
22 injection of a potent photosensitive agent into rats, ischemic lesions were formed by  
23  
24 irradiating the left parietal convexities of the exposed skulls under a light with a specific  
25  
26 wavelength. Free radicals were released, damaging the endothelium of the cerebral vessels  
27  
28 and inducing platelet aggregation. Furthermore, this pathology causes thrombosis in cerebral  
29  
30 parenchymal vessels and results in irreversible hypoxic-ischemic brain damage (HIBD).  
31  
32 Because of the advantages of a stable location and infarction volume, a low mortality rate,  
33  
34 and a good replication rate, the stroke model is widely used in current studies of brain injury.  
35  
36 In this study, we successfully induced a cortical ischemic infarction model in rats in which  
37  
38 the BBB was also damaged. The primary pathological features of stroke were induced, and  
39  
40 the volumes of infarction were consistent. No infarction and no burn were observed in the  
41  
42 sham-group, indicating that the light stimulation alone did not induce the infarction and that it  
43  
44 acts as a good control.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56  
57 Delayed neuron death (DND) is an important pathology of cerebral ischemia and  
58  
59 cerebral degenerative disease. Cell apoptosis was the primary DND pattern after an acute  
60  
61

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

HIBD, which aggravated the injury of sub-acute or chronic cerebral infarction [15, 16]. In our study, axonal pathologies were observed via the TEM at 7 days after PCI, including many edemas in the axoplasm of axons that have no medulla sheath, and thickening or shrinkage in the sheaths of the axons that have a medulla sheath. However, these conditions improved after sNgR-Fc treatment. The administration of the soluble NgR1 fusion protein (sNgR-Fc) effectively blocked the interaction of myelin molecules with NgR1 and promoted axon sprouting and functional recovery after spinal cord injuries[7–9], or dorsal root rhizotomy[10]. A previous study found that Nogo-A is involved in the secondary axonal degeneration of the thalamus with cerebral infarction in hypertensive rats [17] and after a focal ischemic stroke [18]. Anti-Nogo-A antibody improved behavioral outcome and corticospinal plasticity but did not decrease the infarct volume after experimental stroke [11]. In this study, sNgR-Fc did not cause any difference on infarct volume, but still provided protection of axons as observed in TEM.

Nogo-A, MAG and OMgp were considered to be the inhibitory factors of axonal regeneration in the CNS. NgR1 mediates their inhibitory effect via two co-receptors, p75 and Lingo-1, and transduces the signals via RhoA and its downstream pathways [19, 20]. In this study, the level of the GTP-RhoA protein in the model group was significantly higher than that of the sham-operation group. With the treatment of sNgR-Fc, the level of the GTP-RhoA protein was significantly decreased, suggesting that sNgR-Fc may promote axonal recovery by preventing the activation of RhoA after cerebral infarction.

The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway is a powerful signaling pathway under the stresses of ultraviolet light, radiation and inflammation [21–23]. In publications on neuronal apoptosis, some of the proteins in the

mitogen-activated protein kinases (MAPK) signaling pathways have been well-studied in recent years. The MAPK signaling pathway is a family of serine/threonine kinases that include three members: the extracellular signal-regulated protein kinases (ERK), JNK and p38 [24]. The JNK/SAPK and p38 are induced by cellular stress and some of the cytokines. The JNK protein can be activated by many stress stimulators, such as lipopolysaccharide (LPS), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-1 or ultraviolet light. Activation of the JNK signaling pathway is related to cell apoptosis [24]. Following its activation, JNKs may phosphorylate specific sites of some of the transcription factors, such as ATF-2, SAP-1 and Elk-1, and increase the expression of genes, subsequently increasing the synthesis of proteins that may participate in the apoptosis pathway and cause cell death [25]. We found high levels of p-JNK, p-c-JUN and p-ATF-2 after stroke injury, indicating that cortical infarction activates the SAPK/JNK signal pathway and leads to the pathology of tissues and cells. The administration of sNgR-Fc decreased the activation of those proteins, suggesting that sNgR-Fc has the potential to prevent or decrease the activation of the SAPK/JNK signal pathway. We previously identified that sNgR-Fc binds to Nogo66, OMgp, and MAG [9] and inhibited the Nogo66-NgR interaction [6]. sNgR-Fc may protect axons by inhibiting the interaction of Nogo-A-NgR1 after stroke injury, decreasing the activation of RhoA and JNK. A schematic diagram illustrating the proposed mechanism for sNgR-Fc on axons in stroke is shown in Figure 4: In normal conditions, the cortex expresses low levels of Nogo-A and NgR1. However, cortical infarction under stroke injury increases the expression of Nogo-A and NgR1. Nogo-A activates RhoA and JNK signaling pathways via interacting with NgR1 and then results in pathological changes on axons. sNgR-Fc perturbs the interaction of Nogo-A and NgR1, decreases the activation of RhoA and JNK signaling pathways and

relieving the pathological changes of axons.

1  
2 RhoA regulates the intracellular microfilament associated with cell proliferation through a  
3  
4 series of complex mechanisms [26]. Previous studies have observed that RhoA stimulates Jun  
5  
6 expression through the Rho-associated kinase (ROCK), which phosphorylates c-Jun and  
7  
8 ATF2 after binding to the c-Jun promoter [27]. In this study, we observed that changes in the  
9  
10 expression of p-JNK, p-c-Jun and p-ATF-2 were consistent with changes in the GTP-RhoA  
11  
12 level following both the cerebral infarction and the sNgR-Fc treatment. These findings  
13  
14 suggest that sNgR-Fc can relieve the axonal pathology partially by decreasing the activation  
15  
16 of the SAPK/JNK signal pathways.  
17  
18  
19  
20  
21  
22

23  
24 In summary, pathological changes in axons were induced by the cerebral  
25  
26 hypoxia-ischemia for an extended period after the cortical infarction. This phenomenon may  
27  
28 be associated with the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. We  
29  
30 determined that an NgR1 antagonist, sNgR-Fc, alleviated axonal pathology changes and  
31  
32 prevented the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. Further studies  
33  
34 should be performed before this treatment is used in a clinical study.  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Acknowledgements**

44  
45 This study was supported by funding from the NSFC (81272062, 81071030), Science  
46  
47 and Technology Foundation of Guangdong Province, China (2012B031800286 ,  
48  
49 2010B031600089) and the Fundamental Research Funds for the Central Universities  
50  
51 (09ykpy31). The funders had no role in the study design, data collection, analysis, decision to  
52  
53 publish or the preparation of the manuscript. Biogen Idec, Inc. provided the sNgR-Fc in the  
54  
55 study.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Disclosure of potential conflicts of interest

The authors indicate no potential conflicts of interest.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

1. Bühnemann C, Scholz A, Bernreuther C, Malik CY, Braun H, Schachner M et al (2006)  
Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke  
lesions of adult rats. *Brain* 129:3238–3248
2. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA et al (2000)  
Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal  
antibody IN-1. *Nature* 403:434–439
3. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E et al (2002)  
Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite  
outgrowth. *Neuron* 35:283–290
4. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL et al (2002)  
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite  
outgrowth. *Nature* 417:941–944
5. GrandPre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal  
regeneration. *Nature* 417:547–551
6. Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E (2009) Blockade of Nogo receptor  
ligands promotes functional regeneration of sensory axons after dorsal root crush. *J*  
*Neurosci* 29:6285–6295
7. Ji B, Li M, Budel S, Pepinsky RB, Walus L, Engber TM et al (2005) Effect of combined  
treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord  
injury. *Eur J Neurosci* 22:587–594
8. Lee JK, Kim JE, Sivula M, Strittmatter SM (2004) Nogo receptor antagonism promotes  
stroke recovery by enhancing axonal plasticity. *J Neurosci* 24:6209–6217

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
9. Li S, Liu BP, Budel S, Li M, Ji B, Walus L et al (2004) Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. *J Neurosci* 24:10511–10520
10. MacDermid VE, McPhail LT, Tsang B, Rosenthal A, Davies A, Ramer MS (2004) A soluble Nogo receptor differentially affects plasticity of spinally projecting axons. *Eur J Neurosci* 20:2567–2579
11. Wiessner C, Bareyre FM, Allegrini PR, Mir AK, Frentzel S, Zurini M, et al (2003) Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. *J Cereb Blood Flow Metab.* 23:154-65.
12. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD (1985) Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol* 17:497-504
13. Gao M, Zhu SY, Tan CB, Xu B, Zhang WC, Du GH (2010) Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats. *J Asian Nat Prod Res* 12:407–418
14. Zheng YQ, Liu JX, Wang JN, Xu L (2007) Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. *Brain Res* 1138:86–94
15. Culmsee C, Plesnila N (2006) Targeting Bid to prevent programmed cell death in neurons. *Biochem Soc Trans* 34:1334–1340
16. Plesnila N, Zhu C, Culmsee C, Gröger M, Moskowitz MA, Blomgren K (2004) Nuclear



translocation of apoptosis-inducing factor after focal cerebral ischemia. *J Cereb Blood Flow Metab* 24:458–466

17. Wang F, Liang Z, Hou Q, Xing S, Ling L, He M et al (2007) Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. *Neurosci Lett* 417:255–260
18. Cheatwood JL, Emerick AJ, Schwab ME, Kartje GL (2008) Nogo-A expression after focal ischemic stroke in the adult rat. *Stroke* 39:2091–2098
19. Kubo T, Hata K, Yamaguchi A, Yamashita T (2007) Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. *Curr Pharm Des* 13:2493–2499
20. Kubo T, Yamashita T (2007) Rho-ROCK inhibitors for the treatment of CNS injury. *Recent Patents CNS Drug Discov* 2:173–179
21. Schwab TS, Madison BB, Grauman AR, Feldman EL (2005) Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. *Apoptosis* 10:831–840
22. Zhang HM, Yuan J, Cheung P, Luo H, Yanagawa B, Chau D et al (2003) Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication. *J Biol Chem* 278:33011–33019
23. Koh SH, Lee YB, Kim KS, Kim HJ, Kim M, Lee YJ et al (2005) Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. *Eur J Neurosci* 22:301–309
24. Yasuda S, Sugiura H, Tanaka H, Takigami S, Yamagata K (2011) p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. *Cent Nerv Syst Agents Med*

Chem. 11:45-59.

- 1  
2 25. Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N et al (2007) The  
3  
4 mitogen-activated protein kinase p38 regulates activator protein 1 by direct  
5  
6 phosphorylation of c-Jun. *Int J Biochem Cell Biol* 39:2278–2288  
7  
8  
9  
10 26. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS (2004) The  
11  
12 small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. *Mol*  
13  
14 *Cell* 14:29–41  
15  
16  
17  
18 27. Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. *Curr Opin Cell Biol*  
19  
20  
21 9:240–246  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Figure Legends

1 **Figure 1. The morphology and characteristics of the rat brain after a stroke induced by**  
2 **photothrombotic cortical injury.** (a) Representative photographs of the coronal brain  
3 sections stained with 2,3,5-triphenyltetrazolium chloride in rats, (b) sham-operated rats, (c)  
4 and photothrombotic cortical injury (PCI) rats. White indicates the infarct area (arrow).  
5  
6  
7  
8  
9

10  
11  
12 **Figure 2. The protective effect of sNgR-Fc on axon neurons under transmission electron**  
13 **microscope after stroke injury.** Ultrastructural appearances of morphology of axons in  
14 sham-operated, PBS and sNgR-Fc groups: (a) Normal unmyelinated axons in sham-operated  
15 group; (b) Extensive edema, axon deformity, dilution of cytoplasmic matrices and axonal  
16 fusion in stroke model; (c) Slight edema and dilution of cytoplasmic matrices with the  
17 treatment of sNgR-Fc in stroke model; (d) Normal myelinated axons in sham-operated group;  
18 (e) Thickening, shrinking or amyloidosis was more in stroke model; (f) Little demyelination  
19 and no amyloidosis of the myelin sheath were found with the treatment of sNgR-Fc in stroke  
20 model; (g) Normal synapses in the sham-operated group; (h) Widened and swollen synaptic  
21 cleft in stroke model; (i) Approximately normal synapses with the treatment of sNgR-Fc in  
22 stroke model. Arrows show the changes in axons.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Figure 3. The RhoA, SAPK/JNK signaling pathways after stroke injury and with the**  
39 **treatment of sNgR-Fc under Western blotting.** The levels of p-JNK, p-c-JUN, p-ATF-2  
40 and GTP-RhoA increased after stroke injury. Treatment with sNgR-Fc decreased the levels of  
41 p-JNK, p-c-JUN, p-ATF-2 and GTP-RhoA to normal levels.  
42  
43  
44  
45  
46  
47

48 **Figure 4. The diagram of the signaling pathways involved in the sNgR-Fc on axons after**  
49 **stroke injury.** In the normal condition, there is low level of Nogo-A and NgR1 in the cortex.  
50 However, the expression of Nogo-A and NgR1 is increased under stroke injury. The increased  
51 Nogo-A binds with NgR1 to activate the downstream pathways of RhoA and JNK, and then  
52 results in axonal pathology. The treatment of sNgR-Fc inhibits the interaction of Nogo-A and  
53 NgR1, decreases the activation of RhoA and JNK signaling pathways and then relieves  
54 axonal pathology.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**The effect of an NgR1 antagonist on the neuroprotection of cortical axons after cortical infarction in rats**

Running title: The neuroprotection of NgR1 antagonist on cortical axons

Hong Zhan<sup>1,6</sup>, Shu-Jie Sun<sup>4,6</sup>, Jie Cai<sup>1</sup>, Ying-Qing Li<sup>1</sup>, Chun-Lin Hu<sup>1</sup>, Daniel H.S. Lee<sup>3</sup>, Kwok-Fai So<sup>2,5</sup>, Xin Li<sup>1</sup>

<sup>1</sup>Department of Emergency, The First Affiliated Hospital, Sun Yat-sen University, 58 ZhongShan II, Guangzhou, Guangdong, 510080, China

<sup>2</sup>Department of Anatomy and The State Key Laboratory of Brain and Cognitive sciences, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China

<sup>3</sup>Roche R&D Center (China) Ltd. 720 Cai Lun Road, Building, Pudong, Shanghai 201203, China

<sup>4</sup>Emergency Department, East Hospital of TongJi University, 150 Jimo Road, Shanghai, People's Republic of China

<sup>5</sup>GHM Institute of CNS Regeneration, Jinan University, Guangzhou, China

<sup>6</sup>These authors contributed equally to this work.

**Correspondence to:**

**Xin Li, MD**

Associate Professor

Department of Emergency

The First Affiliated Hospital

Sun Yat-sen University

58 ZhongShan Road II, Guangzhou, Guangdong, 510080, China

Telephone: +86-20-28823350

Fax: +86-20-28823350.

E-mail: xlidoct@qq.com

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Abstract

1 We investigated the effect of the soluble Nogo66 receptor (sNgR-Fc) on the protection of  
2 cortical axons after cortical infarction in rats. The cortical infarction was induced by  
3  
4 cortical axons after cortical infarction in rats. The cortical infarction was induced by  
5  
6 photothrombotic cortical injury (PCI) in Sprague Dawley rats, after which sNgR-Fc was  
7  
8 injected into the lateral ventricle. The ipsilesional cortices were harvested for analyses using  
9  
10 histochemical and transmission-electron microscope techniques. The involved signaling  
11  
12 pathways, which include RhoA, JNK, c-JUN and ATF-2, were detected by Western blot.  
13  
14 Serious pathologies were found in the brains of the rats after injury, including edemas in the  
15  
16 axoplasms of axons that have no medulla sheath and a thickening or shrinkage in the sheath  
17  
18 of the axons that have medulla sheathes. However, these pathologies improved after sNgR-Fc  
19  
20 treatment. The levels of GTP-RhoA, p-JNK, p-c-JUN and p-ATF-2 in the PCI group were  
21  
22 increased when compared with their levels in the sham-operation group ( $P < 0.05$ ), and  
23  
24 animals receiving the sNgR-Fc treatment showed lower expression levels of these proteins  
25  
26 when compared with the sham-operation group ( $P < 0.05$ ). Our results suggest that sNgR-Fc  
27  
28 can alleviate the pathological changes of axons following cortical infarction via decreasing  
29  
30 the activation of RhoA/JNK signaling pathways.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **Key words:** Nogo-66 receptor; Axon; Cortical infarction; Regeneration; Signal pathway  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

1 A brain infarction (also known as an ischemic stroke) is caused by the blockage of a cerebral  
2 artery by a blood clot, which results in the following effects: a critical reduction in blood flow,  
3  
4 ischemia, anoxia, and, finally, ischemic necrosis or encephalomalacia in the brain. This  
5  
6 condition is characterized clinically by high morbidity, high mortality, high disability rate,  
7  
8 high recurrence rates, and it is difficult to treat. Because our population is aging, stroke is  
9  
10 becoming a more serious threat and an urgent medical problem. Previous studies have shown  
11  
12 that the central nerve system cannot regenerate after injury, as a result of factors that include  
13  
14 the insufficiency of neural progenitor cells (NPCs) and a microenvironment that inhibits the  
15  
16 regeneration of neurons [1]. Recent studies have demonstrated that the inhibition of axon  
17  
18 regeneration after injuries to the central nervous system (CNS) were associated with several  
19  
20 CNS myelin proteins, including Nogo-A, myelin-associated glycoprotein (MAG), and  
21  
22 oligodendrocyte myelin glycoprotein (OMgp). These three proteins bind to the Nogo-66  
23  
24 receptor (NgR1), which then leads to the downstream activation of RhoA (Ras homolog gene  
25  
26 family, member A) via two transmembrane proteins, LINGO-1 and p75; these proteins inhibit  
27  
28 the activity in neurons and their axons [2–4]. Jun N-terminal kinases (JNKs) are intracellular  
29  
30 molecules related to stress stimuli. The activation of these molecules mediates many types of  
31  
32 injury-induced apoptosis and plays a role in the regeneration of axons. However, the role of  
33  
34 the JNK-signaling pathway in the presence of a brain infarction is still unclear. The  
35  
36 administration of sNgR-Fc, a recombinant rat soluble NgR-Fc fusion protein [5], has been  
37  
38 found to block the interaction of myelin proteins with NgR1 effectively and to promote the  
39  
40 regeneration of axons in rodent models of CNS injuries such as spinal cord injury [6–10]. A  
41  
42 previous study has shown that anti-Nogo-A antibody promoted the behavioral outcome and  
43  
44 corticospinal plasticity in a rat stroke model [11]. In this study, we established a stroke model  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 in rats and observed the effects of sNgR-Fc on the axonal pathology and the involved  
3 RhoA/JNK signaling pathways after cortical infarction.  
4  
5  
6

## 7 **Experimental Procedure**

### 8 **Animals**

9  
10 The animal experiments were approved by the Committee for the Use of Live Animals in  
11 Teaching and Research at the Sun Yat-sen University. All of the experiments were performed  
12 in a fully randomized and blinded fashion.  
13  
14  
15  
16  
17  
18  
19  
20

### 21 **Photothrombotic cortical injury**

22 **Photothrombotic ischemia was induced in the rat parietal cortex using previously described**  
23 **methods [9,11,12] with the modifications as outlined below.** Twenty seven male SD rats  
24 weighing 250 g were anesthetized by an intraperitoneal injection of ketamine (80 mg/kg) and  
25 xylazine (8 mg/kg). Dilute Rose-Bengal in saline (40 mg/kg body weight) was infused into  
26 the femoral vein. The portion of the skull exposed at 3 mm posteriorly to the bregma and 3  
27 mm laterally from the midline was illuminated with a cold, white light beam (Volpi Intralux  
28 6000, 150 W; Volpi AG, Schlieven, Switzerland) for 8 min at maximum output via a  
29 fiber-optic bundle with a 10 mm aperture. The animals were randomly grouped into  
30 sham-operation (operation + Rose-Bengal), PBS (operation + Rose-Bengal + PBS), or  
31 sNgR-Fc (operation + Rose-Bengal + sNgR-Fc) groups ( $n = 9$  for each group). A solution of  
32 sNgR-Fc (400  $\mu\text{g}/\text{kg}$  body weight) in 10 $\mu\text{l}$  PBS or equivalent PBS was only once injected  
33 into the ipsilateral ventricle using a 26-gauge sterile microsyringe 24 h after photothrombotic  
34 cortical injury [11]. The site of injection was at 1 mm posteriorly to the bregma and 1.5 mm  
35 laterally from the midline, and the depth of injection was about 3.5~4.0 mm. For each group,  
36 the whole cerebrum of 3 animals was collected 24 h after injury for tissue staining. The  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 ipsilateral cortex of peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm  
3 laterally from the midline of rats was collected at 27 d after injury for electron microscopy  
4 examination ( $n = 3$  for each group) and for Western blotting ( $n = 3$  for each group).  
5  
6  
7  
8  
9

### 10 **Triphenyltetrazolium chloride staining**

11  
12 To evaluate the extent of cortical infarction, we used 2, 3, 5-Triphenyltetrazolium chloride  
13 (TTC) to assess cerebral injury. At 24 h after PCI, the animals were sacrificed using an  
14 overdose of pentobarbital sodium (150 mg/kg, Alcon-Couvreur, Rijksweg, Puurs, Belgium).  
15  
16 The brains were removed immediately and then were chilled at  $-30\text{ }^{\circ}\text{C}$  for 4 min to slightly  
17 freeze the tissue. Two-mm coronal sections from the olfactory bulb to the cerebellum were  
18 prepared, stained with 1.5% TTC (Genetime) at  $37\text{ }^{\circ}\text{C}$  for 30 min, and fixed in 10% buffered  
19 formalin solution.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **Transmission electron microscopy**

32  
33 Seven days after PCI, the peripheral penumbra at 7 mm posteriorly to the bregma and 3 mm  
34 laterally from the midline on the injury side was removed and immediately cut into  $0.5\text{ cm}^3$   
35 cubes at  $0\text{ }^{\circ}\text{C}$ , fixed with 4% paraformaldehyde for 4 h, and washed with PBS. Then, the  
36 tissue was fixed with 2% osmic acid for 2 h, washed with pure water, dehydrated with a  
37 mixture of ethanol, propylene oxide, and resin, embedded in pure resin, and ultramicrocut  
38 and stained with uranyl acetate and lead citrate [13, 14]. The sections were observed under an  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 66 **Western blotting**

67  
68 The cortex from the injury side was collected at 7 days after injury and homogenized in a  
69 lysis buffer (in mM: Tris, 10, pH 7.4; NaCl, 150; EDTA, 1; EGTA, 1; 10% protease inhibitor,  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000



1 centrifuged at 13,500 rpm for 30 min at 4 °C. The supernatant was aliquoted and stored at  
2 -80 °C until its use. The supernatant was measured for its protein concentration using a  
3  
4 Bio-Rad DC Protein Assay Kit (Bio-Rad Laboratories, CA, USA). A 40 µg aliquot of protein  
5  
6 from each sample was subjected to 5–12% SDS–polyacrylamide gel electrophoresis and  
7  
8 transferred onto a PVDF membrane. Each membrane was blocked with 5% non-fat milk and  
9  
10 2% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h  
11  
12 at room temperature and then probed with rabbit anti-p-JNK (Cell Signaling Technology,  
13  
14 MA, USA), anti-p-c-JUN (Cell Signaling Technology), p-ATF-2 (Cell Signaling  
15  
16 Technology), total-JNK (Cell Signaling Technology) and total-RhoA antibodies at 4 °C  
17  
18 overnight. As a gel loading control, β-actin was used. After washing, the membranes were  
19  
20 incubated for 2 h with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:2000;  
21  
22 DakoCytomation, Denmark). Its immunoreactivity was visualized using the Amersham  
23  
24 enhanced chemiluminescence kit (Amersham, Piscataway, NJ, USA). The protein loading  
25  
26 was controlled using the goat antibody against β-actin (C-11; Santa Cruz Biotechnology).  
27  
28 The quantification of the results was performed by densitometry, and the results were  
29  
30 analyzed as total integrated densitometric values (arbitrary units). The protein GTP-RhoA  
31  
32 was pulled down using a RhoA activation assay kit, according to the manufacturer's  
33  
34 instruction (Cytoskeleton, Denver, CO, USA) and assayed by Western blotting using an  
35  
36 antibody against RhoA (Cytoskeleton). All experiments for Western blotting were performed  
37  
38 with 3 animals in each group, and the samples were run on the gels as individual animals.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 **Data and statistical analysis**

55 The values are presented as the mean ± SD. The statistical analyses was performed  
56  
57 using Student's t-test for comparisons between two groups or the one-way analysis of  
58  
59 variance (ANOVA) followed by post-hoc tests (Student-Neuman-Keuls) for comparisons of  
60  
61  
62  
63  
64  
65

more than two groups. The data were analyzed statistically with the software SPSS 12.0. The significance level was set at  $P < 0.05$ .

## Results

### Measurement of brain infarct volume and identification of blood brain barrier integrity

After TTC staining, the rats in the sham group did not appear to have any infarctions (Fig. 1b). However, the right parietal lobes of the rats 24 h after PCI presented pale infarctions that were bowl-shaped, with the bottom pointing to the lateral ventricle; these infarctions affected the entire cortex. The total infarct volumes were  $297.1 \pm 23.4 \mu\text{l}$  in the PBS group and  $285.4 \pm 19.7 \mu\text{l}$  for the sNgR-Fc group respectively before the treatment. The locations of the infarctions were stable, and the infarctions showed similar volumes to those in the rats (Fig. 1).

### Pathological changes of axons

The morphology of ischemic penumbra on the injury side was evaluated using TEM at 7 days after PCI. Compared with the normal axons observed in the sham group (Fig. 2a), more serious pathologies were observed in the PCI group (Fig. 2b). For the axons without a medulla sheath, many edemas, dilutions of cytoplasmic matrices, and axonal fusions or dissolutions were found. Occasionally, we observed that oligodendrocytes appeared to “swallow” the axons (Fig. 2b). For axons with a medulla sheath, compared with the sham group, thickening or shrinking was more in the axoplasm of the fibers, and amyloidosis and swollen axons were observed at a higher rate. In addition, the axolemma were found to be separated from the inner layers of the myelin (Fig. 2e). In addition, there were only minor pathological changes, including slight nuclear edemas with complete nucleoli, slightly swollen mitochondria, and slightly widened endoplasmic reticula with complete ribosomes

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

and Golgi bodies. In unmyelinated axons, there were some axonal edemas, axonal deformities, and dilutions of cytoplasmic matrices; in addition, there were no axonal fusions or cytophagic effects of oligodendrocytes (Fig. 2c). In myelinated axons, the morphology of axons was almost normal. There was little demyelination and no amyloidosis of the myelin sheath was found (Fig. 2f). Compared with normal synapses (Fig. 2g), the synaptic cleft widened, and there was edema in the PBS group (Fig. 2h). However, no clear edema or widening of the synaptic cleft was observed in the group that received the sNgR-Fc treatment (Fig. 2i).

### **sNgR-Fc inhibited RhoA signal pathway**

The level of GTP-RhoA in the PBS group was significantly higher than that in the sham-operation group ( $P < 0.05$ ). After treatment with sNgR-Fc, the level of GTP-RhoA was significantly decreased. Moreover, the level of Total-RhoA was not different among the three groups (Fig.3, Table 1). **These data indicate that sNgR-Fc could decrease the activation of RhoA.**

### **sNgR-Fc inhibit the activation of SAPK/JNK signal pathway**

The levels of p-JNK1, 2 and its downstream targets, p-c-JUN and p-ATF-2, in the cortex around the infarcts in the PCI group were significantly higher compared with those in the sham operation group ( $P < 0.05$ ). In contrast, the cortex in the sNgR-Fc-treated group showed, on average, reductions in the levels of p-JNK1, 2, p-c-JUN and p-ATF-2 to their basal levels ( $P < 0.05$ ). The levels of total JNK1, 2 were not different among the three groups ( $P > 0.05$ ). These results demonstrate that the cortical infarction injury activates the SAPK/JNK signal pathway and that treatment with sNgR-Fc has the potential to decrease or prevent this activation (Fig.3, Table 1).

## Discussion

1 Watson et al reported a stroke model induced by a photochemical method in 1985 [12]. The  
2 principle underlying this model was based on a photochemical reaction. Following the  
3  
4 injection of a potent photosensitive agent into rats, ischemic lesions were formed by  
5  
6 irradiating the left parietal convexities of the exposed skulls under a light with a specific  
7  
8 wavelength. Free radicals were released, damaging the endothelium of the cerebral vessels  
9  
10 and inducing platelet aggregation. Furthermore, this pathology causes thrombosis in cerebral  
11  
12 parenchymal vessels and results in irreversible hypoxic-ischemic brain damage (HIBD).  
13  
14 Because of the advantages of a stable location and infarction volume, a low mortality rate,  
15  
16 and a good replication rate, the stroke model is widely used in current studies of brain injury.  
17  
18 In this study, we successfully induced a cortical ischemic infarction model in rats in which  
19  
20 the BBB was also damaged. The primary pathological features of stroke were induced, and  
21  
22 the volumes of infarction were consistent. No infarction and no burn were observed in the  
23  
24 sham-group, indicating that the light stimulation alone did not induce the infarction and that it  
25  
26 acts as a good control.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Delayed neuron death (DND) is an important pathology of cerebral ischemia and  
41  
42 cerebral degenerative disease. Cell apoptosis was the primary DND pattern after an acute  
43  
44 HIBD, which aggravated the injury of sub-acute or chronic cerebral infarction [15, 16]. In our  
45  
46 study, axonal pathologies were observed via the TEM at 7 days after PCI, including many  
47  
48 edemas in the axoplasm of axons that have no medulla sheath, and thickening or shrinkage in  
49  
50 the sheaths of the axons that have a medulla sheath. However, these conditions improved  
51  
52 after sNgR-Fc treatment. The administration of the soluble NgR1 fusion protein (sNgR-Fc)  
53  
54 effectively blocked the interaction of myelin molecules with NgR1 and promoted axon  
55  
56 sprouting and functional recovery after spinal cord injuries[7–9], or dorsal root rhizotomy[10].  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

A previous study found that Nogo-A is involved in the secondary axonal degeneration of the thalamus with cerebral infarction in hypertensive rats [17] and after a focal ischemic stroke [18]. Anti-Nogo-A antibody improved behavioral outcome and corticospinal plasticity but did not decrease the infarct volume after experimental stroke [11]. **In this study, sNgR-Fc did not cause any difference on infarct volume, but still provided protection of axons as observed in TEM.**

Nogo-A, MAG and OMgp were considered to be the inhibitory factors of axonal regeneration in the CNS. NgR1 mediates their inhibitory effect via two co-receptors, p75 and Lingo-1, and transduces the signals via RhoA and its downstream pathways [19, 20]. In this study, the level of the GTP-RhoA protein in the model group was significantly higher than that of the sham-operation group. With the treatment of sNgR-Fc, the level of the GTP-RhoA protein was significantly decreased, suggesting that sNgR-Fc may promote axonal recovery by preventing the activation of RhoA after cerebral infarction.

The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway is a powerful signaling pathway under the stresses of ultraviolet light, radiation and inflammation [21–23]. In publications on neuronal apoptosis, some of the proteins in the mitogen-activated protein kinases (MAPK) signaling pathways have been well-studied in recent years. The MAPK signaling pathway is a family of serine/threonine kinases that include three members: the extracellular signal-regulated protein kinases (ERK), JNK and p38 [24]. The JNK/SAPK and p38 are induced by cellular stress and some of the cytokines. The JNK protein can be activated by many stress stimulators, such as lipopolysaccharide (LPS), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-1 or ultraviolet light. Activation of the JNK signaling pathway is related to cell apoptosis [24]. Following its activation, JNKs may phosphorylate specific sites of some of the transcription factors, such as ATF-2, SAP-1

1 and Elk-1, and increase the expression of genes, subsequently increasing the synthesis of  
2 proteins that may participate in the apoptosis pathway and cause cell death [25]. We found  
3  
4 high levels of p-JNK, p-c-JUN and p-ATF-2 after stroke injury, indicating that cortical  
5  
6 infarction activates the SAPK/JNK signal pathway and leads to the pathology of tissues and  
7  
8 cells. The administration of sNgR-Fc decreased the activation of those proteins, suggesting  
9  
10 that sNgR-Fc has the potential to prevent or decrease the activation of the SAPK/JNK signal  
11  
12 pathway. We previously identified that sNgR-Fc binds to Nogo66, OMgp, and MAG [9] and  
13  
14 inhibited the Nogo66-NgR interaction [6]. sNgR-Fc may protect axons by inhibiting the  
15  
16 interaction of Nogo-A-NgR1 after stroke injury, decreasing the activation of RhoA and JNK.  
17  
18 A schematic diagram illustrating the proposed mechanism for sNgR-Fc on axons in stroke is  
19  
20 shown in Figure 4: In normal conditions, the cortex expresses low levels of Nogo-A and  
21  
22 NgR1. However, cortical infarction under stroke injury increases the expression of Nogo-A  
23  
24 and NgR1. Nogo-A activates RhoA and JNK signaling pathways via interacting with NgR1  
25  
26 and then results in pathological changes on axons. sNgR-Fc perturbs the interaction of  
27  
28 Nogo-A and NgR1, decreases the activation of RhoA and JNK signaling pathways and  
29  
30 relieving the pathological changes of axons.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 RhoA regulates the intracellular microfilament associated with cell proliferation through a  
44  
45 series of complex mechanisms [26]. Previous studies have observed that RhoA stimulates Jun  
46  
47 expression through the Rho-associated kinase (ROCK), which phosphorylates c-Jun and  
48  
49 ATF2 after binding to the c-Jun promoter [27]. In this study, we observed that changes in the  
50  
51 expression of p-JNK, p-c-Jun and p-ATF-2 were consistent with changes in the GTP-RhoA  
52  
53 level following both the cerebral infarction and the sNgR-Fc treatment. These findings  
54  
55 suggest that sNgR-Fc can relieve the axonal pathology partially by decreasing the activation  
56  
57 of the SAPK/JNK signal pathways.  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

In summary, pathological changes in axons were induced by the cerebral hypoxia-ischemia for an extended period after the cortical infarction. This phenomenon may be associated with the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. We determined that an NgR1 antagonist, sNgR-Fc, alleviated axonal pathology changes and prevented the activation of RhoA/ROCK/JNK/c-Jun signaling pathways. Further studies should be performed before this treatment is used in a clinical study.

### **Acknowledgements**

This study was supported by funding from the NSFC (81272062, 81071030), Science and Technology Foundation of Guangdong Province, China (2012B031800286 , 2010B031600089) and the Fundamental Research Funds for the Central Universities (09ykpy31). The funders had no role in the study design, data collection, analysis, decision to publish or the preparation of the manuscript. Biogen Idec, Inc. provided the sNgR-Fc in the study.

### **Disclosure of potential conflicts of interest**

The authors indicate no potential conflicts of interest.

## References

1. Bühnemann C, Scholz A, Bernreuther C, Malik CY, Braun H, Schachner M et al (2006)  
Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke  
lesions of adult rats. *Brain* 129:3238–3248
2. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA et al (2000)  
Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal  
antibody IN-1. *Nature* 403:434–439
3. Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E et al (2002)  
Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite  
outgrowth. *Neuron* 35:283–290
4. Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL et al (2002)  
Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite  
outgrowth. *Nature* 417:941–944
5. GrandPre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal  
regeneration. *Nature* 417:547–551
6. Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E (2009) Blockade of Nogo receptor  
ligands promotes functional regeneration of sensory axons after dorsal root crush. *J*  
*Neurosci* 29:6285–6295
7. Ji B, Li M, Budel S, Pepinsky RB, Walus L, Engber TM et al (2005) Effect of combined  
treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord  
injury. *Eur J Neurosci* 22:587–594
8. Lee JK, Kim JE, Sivula M, Strittmatter SM (2004) Nogo receptor antagonism promotes  
stroke recovery by enhancing axonal plasticity. *J Neurosci* 24:6209–6217
9. Li S, Liu BP, Budel S, Li M, Ji B, Walus L et al (2004) Blockade of Nogo-66,



myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. *J Neurosci* 24:10511–10520

10. MacDermid VE, McPhail LT, Tsang B, Rosenthal A, Davies A, Ramer MS (2004) A soluble Nogo receptor differentially affects plasticity of spinally projecting axons. *Eur J Neurosci* 20:2567–2579
11. Wiessner C, Bareyre FM, Allegrini PR, Mir AK, Frentzel S, Zurini M, et al (2003) Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. *J Cereb Blood Flow Metab.* 23:154-65.
12. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD (1985) Induction of reproducible brain infarction by photochemically initiated thrombosis. *Ann Neurol* 17:497-504
13. Gao M, Zhu SY, Tan CB, Xu B, Zhang WC, Du GH (2010) Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats. *J Asian Nat Prod Res* 12:407–418
14. Zheng YQ, Liu JX, Wang JN, Xu L (2007) Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. *Brain Res* 1138:86–94
15. Culmsee C, Plesnila N (2006) Targeting Bid to prevent programmed cell death in neurons. *Biochem Soc Trans* 34:1334–1340
16. Plesnila N, Zhu C, Culmsee C, Gröger M, Moskowitz MA, Blomgren K (2004) Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia. *J Cereb Blood Flow Metab* 24:458–466

17. Wang F, Liang Z, Hou Q, Xing S, Ling L, He M et al (2007) Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. *Neurosci Lett* 417:255–260
18. Cheatwood JL, Emerick AJ, Schwab ME, Kartje GL (2008) Nogo-A expression after focal ischemic stroke in the adult rat. *Stroke* 39:2091–2098
19. Kubo T, Hata K, Yamaguchi A, Yamashita T (2007) Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. *Curr Pharm Des* 13:2493–2499
20. Kubo T, Yamashita T (2007) Rho-ROCK inhibitors for the treatment of CNS injury. *Recent Patents CNS Drug Discov* 2:173–179
21. Schwab TS, Madison BB, Grauman AR, Feldman EL (2005) Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. *Apoptosis* 10:831–840
22. Zhang HM, Yuan J, Cheung P, Luo H, Yanagawa B, Chau D et al (2003) Overexpression of interferon-gamma-inducible GTPase inhibits coxsackievirus B3-induced apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway and inhibition of viral replication. *J Biol Chem* 278:33011–33019
23. Koh SH, Lee YB, Kim KS, Kim HJ, Kim M, Lee YJ et al (2005) Role of GSK-3beta activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene. *Eur J Neurosci* 22:301–309
24. Yasuda S, Sugiura H, Tanaka H, Takigami S, Yamagata K (2011) p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. *Cent Nerv Syst Agents Med Chem*. 11:45-59.
25. Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N et al (2007) The mitogen-activated protein kinase p38 regulates activator protein 1 by direct

phosphorylation of c-Jun. *Int J Biochem Cell Biol* 39:2278–2288

- 1  
2 26. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS (2004) The  
3  
4 small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. *Mol*  
5  
6  
7 *Cell* 14:29–41  
8  
9  
10 27. Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. *Curr Opin Cell Biol*  
11  
12  
13 9:240–246  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Figure Legends

1 **Figure 1. The morphology and characteristics of the rat brain after a stroke induced by**  
2 **photothrombotic cortical injury.** (a) Representative photographs of the coronal brain  
3 sections stained with 2,3,5-triphenyltetrazolium chloride in rats, (b) sham-operated rats, (c)  
4 and photothrombotic cortical injury (PCI) rats. White indicates the infarct area (arrow).  
5  
6  
7  
8  
9

10  
11  
12 **Figure 2. The protective effect of sNgR-Fc on axon neurons under transmission electron**  
13 **microscope after stroke injury.** Ultrastructural appearances of morphology of axons in  
14 sham-operated, PBS and sNgR-Fc groups: (a) Normal unmyelinated axons in sham-operated  
15 group; (b) Extensive edema, axon deformity, dilution of cytoplasmic matrices and axonal  
16 fusion in stroke model; (c) Slight edema and dilution of cytoplasmic matrices with the  
17 treatment of sNgR-Fc in stroke model; (d) Normal myelinated axons in sham-operated group;  
18 (e) Thickening, shrinking or amyloidosis was more in stroke model; (f) Little demyelination  
19 and no amyloidosis of the myelin sheath were found with the treatment of sNgR-Fc in stroke  
20 model; (g) Normal synapses in the sham-operated group; (h) Widened and swollen synaptic  
21 cleft in stroke model; (i) Approximately normal synapses with the treatment of sNgR-Fc in  
22 stroke model. Arrows show the changes in axons.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Figure 3. The RhoA, SAPK/JNK signaling pathways after stroke injury and with the**  
39 **treatment of sNgR-Fc under Western blotting.** The levels of p-JNK, p-c-JUN, p-ATF-2  
40 and GTP-RhoA increased after stroke injury. Treatment with sNgR-Fc decreased the levels of  
41 p-JNK, p-c-JUN, p-ATF-2 and GTP-RhoA to normal levels.  
42  
43  
44  
45  
46  
47

48 **Figure 4. The diagram of the signaling pathways involved in the sNgR-Fc on axons after**  
49 **stroke injury.** In the normal condition, there is low level of Nogo-A and NgR1 in the cortex.  
50 However, the expression of Nogo-A and NgR1 is increased under stroke injury. The increased  
51 Nogo-A binds with NgR1 to activate the downstream pathways of RhoA and JNK, and then  
52 results in axonal pathology. The treatment of sNgR-Fc inhibits the interaction of Nogo-A and  
53 NgR1, decreases the activation of RhoA and JNK signaling pathways and then relieves  
54 axonal pathology.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65





Figure 1




Figure 2




Figure 3




Figure 4



Table 1 The density of the key proteins of RhoA and SAPK/JNK signal pathway

	Sham-operated	PBS	sNgR.Fc
GTP-RhoA	1.0±0.14	1.73±0.16 <sup>▲</sup>	1.10±0.13 <sup>▲■</sup>
Total-RhoA	1.0±0.09	0.97±0.11	0.98±0.10
p-ATF-2	1.0±0.12	2.19±0.24 <sup>▲</sup>	1.53±0.22 <sup>▲■</sup>
p-c-JUN	1.0±0.062	1.39±0.139 <sup>▲</sup>	1.12±0.058 <sup>▲■</sup>
p-JNK1	1.0±0.29	2.24±0.27 <sup>▲</sup>	1.30±0.31 <sup>▲■</sup>
p-JNK2	1.0±0.14	1.73±0.12 <sup>▲</sup>	1.02±0.15 <sup>▲■</sup>
Total-JNK1	1.0±0.08	1.01±0.09	1.01±0.08
Total-JNK2	1±0.09	0.99±0.11	0.98±0.12

<sup>▲</sup>P<0.05 vs Sham-operated group; <sup>■</sup>P<0.05 vs PBS group, Mean ±SD, n = 3)